Adrian Abeijon

Investor

Mark Allen

CFO

Juliet Bailin

Partner

Samuel Beyer

Investor

Marc Bhargava

Managing Director

Chris Bischoff

Managing Director

Larry Bohn

Managing Director

Niko Bonatsos

Managing Director

Kristen Camarota

Investor

Teresa Carlson

President, General Catalyst Institute

Kenneth Chenault

Managing Director

Quentin Clark

Managing Director

Mark Crane

Partner

Joel Cutler

Managing Director

Judith Dada

Partner

Christopher Davis

Partner

Kyle Doherty

Managing Director

David Fialkow

Managing Director

Jeannette zu Fürstenberg

Managing Director

Molly Blaauw Gillis

Partner

Julia Goodman

Investor

Drew Gordon

Investor

Philipp Handel

Partner

Steve Herrod

Managing Director

Tony Ho

Investor

Diana Hong

Investor

Mina Hsiang

Associate

Nmachi Jidenma

Partner

Christopher Kauffman

Principal and Member of the Investment Team

Genevieve Kinney

Investor

Zak Kukoff

Principal

Paul Kwan

Managing Director

Nathaniel Levy-Westhead

Partner, Investment Team

Roy Mabrey

Partner, Investment Team

Holly Maloney McConnell

Managing Director

Karanveer Mohan

Managing Director

Alexandre Momeni

Partner

Dipchand Nishar

Managing Director

Deep Nishar

Managing Director

Reva Nohria

Principal

Trevor Oelschig

Managing Director

Tyler Olkowski

Investor

Pranay Orugunta

Healthcare Investor

Mo Punjwani

Associate, Investments

Candace Richardson

Principal

Max Rimpel

Partner

Brian Ru

Principal

Paul Sagan

Investor

Pranav Singhvi

Partner

Bill Skarinka

Associate

Vedant Suri

Investor

Hemant Taneja

Managing Director

Alexander Tran

Managing Director

Catherine Tu

Partner

Adam Valkin

Managing Director

Elena Viboch

Partner

Andrea Wang

Partner

Zeynep Yavuz

Partner

Vincent Zhu

Investor

Past deals in Medical

Stance Health

Pre Seed Round in 2025
Stance Health is a health technology company specializing in musculoskeletal (MSK) care. It develops a health and wellness platform that integrates medical science and technology to deliver evidence-based orthopedic rehabilitation. The company focuses on performance recovery and prevention, offering personalized programs for individuals with MSK conditions. Services include advanced diagnostic tools, tailored rehabilitation plans, and ongoing assessments, helping patients recover, prevent injuries, and improve their overall physical well-being.

Sohar Health

Seed Round in 2025
Sohar Health is a technology company that provides an API-based platform for behavioral health organizations. Its key offerings include automated eligibility verification and AI-powered medical coding, aiming to streamline workflows, enhance patient intake, and boost revenue.

Maxion Therapeutics

Series A in 2025
Maxion Therapeutics develops a novel platform to generate antibody-like therapeutics targeting ion channels and GPCR-driven diseases. The platform incorporates venom-derived knottins into antibody surfaces to create mixtures with optimized drug-like properties, enabling treatments for conditions such as chronic pain, autoimmune disorders, and heart disease. The company aims to deliver long-acting, safe, and effective medications against previously inaccessible targets.

Manas AI

Seed Round in 2025
Manas AI uses proprietary AI, generative computational chemistry, and best-in-class biology to reduce the time and expense of traditional medicinal development while also revolutionizing cancer and rare illness treatments.

Neko Health

Series B in 2025
Neko Health is a Swedish health-tech company focused on transforming healthcare through prevention and early detection. The company has developed innovative medical scanning technology that facilitates comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By utilizing advanced sensor technology and artificial intelligence, Neko Health aims to enhance preventive care and reduce the incidence of common diseases, thereby lowering associated healthcare costs. This approach enables healthcare providers to deliver flexible and cost-effective examinations, ultimately improving the quality of care and emphasizing the importance of preventive health measures.

Oasys Now

Seed Round in 2024
Oasys Now is a platform dedicated to connecting chronic patients with relevant clinical trials worldwide. It uses advanced algorithms to match patients with appropriate trials based on their health data, enhancing treatment options and prioritizing patient privacy.

Medeloop

Series A in 2024
Medeloop accelerates medical discoveries by providing a platform that seamlessly links, harmonizes, and analyzes vast amounts of health data. It pioneers AI techniques to find biomarkers for clinical researchers, shortening the research process and enabling more publications.

Alpha9 Theranostics

Series C in 2024
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.

Primus

Seed Round in 2024
Primus helps elderly people slow the aging process by eliminating loneliness and achieving 'Zero Falls'. We ensure that we are proactive rather than reactive by conducting a series of examinations prior to onboarding elders so that they can be monitored by our in-house medical staff under a personalized care plan.

HarmonyCares

Venture Round in 2024
HarmonyCares specializes in delivering high-quality primary healthcare at home. They offer an integrated model that includes ancillary services such as home health, hospice, palliative care, radiology, and laboratory testing.

Better Health

Series A in 2024
Better Health is a digital platform facilitating peer-to-peer support and supplies management for individuals with chronic conditions such as ostomy, wounds, diabetes, retention, and incontinence. Trusted by major healthcare payers and providers, it improves patient outcomes and reduces care costs through education, engagement, and adherence.

Hona AI

Seed Round in 2024
Hona AI is an AI data platform that collects and maintains healthcare history and records of patients.

Karius

Series C in 2024
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

Chamber Cardio

Seed Round in 2024
Chamber Cardio is a healthcare platform focused on enhancing cardiovascular health services. It aims to transition cardiologists into value-based care by providing a range of services that include panel management, financial metrics, and clinical data integration into a user-friendly dashboard. The platform also offers software support designed to assist healthcare providers in managing complex patient cases effectively. By facilitating value-based contracting, Chamber Cardio ensures that both patients and the healthcare sector receive comprehensive support, ultimately improving treatment accessibility and quality for individuals requiring cardiovascular care.

Summa Health

Acquisition in 2024
Summa Health is a comprehensive healthcare provider that focuses on delivering integrated and coordinated care through a network of hospitals, community health centers, and specialized health services. The organization encompasses a health plan, a physician-hospital organization, and a multi-specialty physician organization, ensuring a wide range of patient care options. Additionally, Summa Health is dedicated to advancing medical knowledge through research and supports various community initiatives via its multiple foundations. Its Cancer Centers are particularly notable, combining advanced treatment technologies and medical expertise with a patient-centered approach to promote holistic healing.

Harbor Health

Series A in 2024
Founded in 2022, Harbor Health is a multi-specialty clinic group based in Austin, Texas. It offers personalized healthcare through technology, co-creating health paths tailored to individuals' goals with specialist guidance when needed.

Phare Health

Seed Round in 2023
Phare Health operates an AI platform that automates the extraction of patient care data from unstructured clinical notes, transforming it into structured data for administrative, operational, and financial teams. This enables healthcare systems to enhance resource management, improve cost recovery, and ensure accurate reimbursement, thereby increasing efficiency and resilience in healthcare operations.

Commure

Venture Round in 2023
Commure is a healthcare technology company that provides an open, cloud-based operating system and developer platform for building interoperable healthcare software. The platform unifies disparate datasets, enables building and deploying health applications on a secure foundation based on HL7 FHIR, and offers an API server, security framework, event service bus, EHR integration, API gateway, flexible data store, UI components, and terminology services. It supports clinicians, nurses, patients, and other health professionals to access and share insights, accelerate software innovation, and collaborate across care facilities, health systems, and payers. The company partners with health systems and digital innovators to advance care delivery with a suite of applications and tools. Commure is headquartered in San Francisco, with offices in Boston, Montreal, and Bogota.

Medeloop

Seed Round in 2023
Medeloop accelerates medical discoveries by providing a platform that seamlessly links, harmonizes, and analyzes vast amounts of health data. It pioneers AI techniques to find biomarkers for clinical researchers, shortening the research process and enabling more publications.

Georgiamune

Series A in 2023
Georgiamune is an immunotherapy company that develops oncology-focused treatments. It advances next-generation immunotherapies and homeostatic therapies aimed at cancer and autoimmune diseases. The company's approach targets immune signaling pathways to reprogram the immune system and restore immune homeostasis, helping patients fight cancer and autoimmune conditions.

Neko Health

Series A in 2023
Neko Health is a Swedish health-tech company focused on transforming healthcare through prevention and early detection. The company has developed innovative medical scanning technology that facilitates comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By utilizing advanced sensor technology and artificial intelligence, Neko Health aims to enhance preventive care and reduce the incidence of common diseases, thereby lowering associated healthcare costs. This approach enables healthcare providers to deliver flexible and cost-effective examinations, ultimately improving the quality of care and emphasizing the importance of preventive health measures.

Berry Health

Pre Seed Round in 2023
Berry Health is a consumer health startup specializing in remote diagnosis and treatment of various chronic medical conditions. It offers online private medical consultations, prescription drugs, and nationwide delivery, aiming to improve patients' lives by addressing under-served and stigmatized conditions while increasing patient agency.

Memora Health

Venture Round in 2023
Memora Health is a San Francisco-based healthcare technology company that develops an intelligent care enablement platform to automate outpatient communication and digital workflows. The platform helps clinicians focus on top-of-license practice by digitizing and triaging patient-reported concerns and data, enabling proactive two-way communication and support for patients along complex care journeys, and it partners with health systems, health plans, and digital health companies to transform care delivery for care teams and patients.

Maribel Health

Series A in 2023
Maribel Health develops, builds, and operates advanced clinical care models in the home and community to expand health system capacity and improve patient access. The company provides a healthcare technology system for home-based care and also offers assessment and planning for home- and community-based services to support local markets and strategic needs, enabling healthcare organizations to deliver care more efficiently and reach more patients.

Faro Health

Series A in 2023
Faro Health develops a cloud-based medical platform that standardizes, automates, and streamlines clinical trial processes. Its system handles administrative burdens, allowing clinical researchers to focus on critical decisions that drive clinical value.

Vial

Series A in 2022
Vial is a biotech company focused on transforming drug development by enabling cheaper, scalable clinical trials. It leverages computationally designed therapeutics and automated trial processes to advance programs in clinics, supporting biotechnology companies to move programs through various trial phases and partner with clinics to expand access and speed up development.

Vial

Series B in 2022
Vial is a biotech company focused on transforming drug development by enabling cheaper, scalable clinical trials. It leverages computationally designed therapeutics and automated trial processes to advance programs in clinics, supporting biotechnology companies to move programs through various trial phases and partner with clinics to expand access and speed up development.

Redesign Health

Series C in 2022
Founded in 2018, Redesign Health is a global venture builder empowering founders to launch and scale transformative healthcare companies. Since its inception, it has supported over two dozen companies impacting more than ten million lives across various healthcare sectors.

Plume Clinic

Series B in 2022
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.

Homeward

Series B in 2022
Homeward delivers innovative rural health services for over 60 million Americans residing in rural communities. It employs multidisciplinary care teams offering both virtual and on-site care via mobile units, along with remote monitoring to enhance patient connections to high-quality, affordable healthcare.

Examedi

Series A in 2022
Examedi is a healthcare startup that facilitates at-home medical services by connecting patients with independent healthcare providers, including nurses and lab technicians. The company's telemedicine platform allows patients to book diagnostic tests and examinations from the comfort of their homes, focusing on services such as blood tests, pregnancy tests, general check-ups, and COVID-19 testing. By streamlining the scheduling process and offering affordable access to various medical tests, Examedi aims to enhance patient convenience and improve healthcare delivery.

Flexpa

Seed Round in 2022
Founded in 2021, Flexpa is a San Francisco-based company that develops APIs to integrate claims histories into digital health and fintech apps. Its platform also digitizes data from various hardware providers, interprets it, and creates analytics dashboards for healthcare providers to determine treatment plans.

Odyssey Therapeutics

Series B in 2022
Odyssey Therapeutics is a biotechnology company focused on the development of next-generation immunomodulators and oncology medicines. By leveraging an integrated drug-hunting engine, the company aims to enhance the efficiency of drug discovery, unlocking high-potential targets while reducing the risk of attrition during the development process. Odyssey is committed to advancing precision medicine in the healthcare sector, with a product pipeline designed to facilitate a faster transition to clinical development, thereby improving treatment options for patients with various health conditions.

Osmind

Series B in 2022
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.

Loop

Series B in 2022
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

Alinea Health

Venture Round in 2022
Alinea Health is a health-tech startup that provides solutions for corporate health. It utilizes large amounts of data and proprietary algorithms to assist the client company's beneficiaries in navigating their health plans, providing personalized and unbiased guidance, recommendations from the most effective doctors in the accredited network, and conveniences such as scheduling consultations and exams. In addition to continuous monitoring, its doctors use the Lifestyle Medicine methodology to promote a healthy lifestyle and lower the risk of developing chronic diseases.

Homeward

Series A in 2022
Homeward delivers innovative rural health services for over 60 million Americans residing in rural communities. It employs multidisciplinary care teams offering both virtual and on-site care via mobile units, along with remote monitoring to enhance patient connections to high-quality, affordable healthcare.

Story Health

Series A in 2022
Story Health Corporation is a healthcare technology company founded in 2020 and based in Saratoga, California. The company develops intelligent embedded virtualized clinical care software tools designed to assist healthcare specialists, including neurologists and primary care physicians, in understanding medical situations and making informed clinical decisions. Story Health's platform utilizes data from high-frequency sources to enhance therapy management through virtual protocols and adaptive machine learning. By focusing on patient-centered design, Story Health aims to bridge the gap between clinical evidence and real-world patient experiences, enabling clinicians to effectively address the physiological effects of disease and therapy.

Ro

Venture Round in 2022
Ro is a telehealth company founded in New York City in 2017. It operates digital health clinics for men's and women's health, smoking cessation, and offers a vertically integrated primary care platform that provides high-quality, affordable healthcare without the need for insurance.

Dewpoint Therapeutics

Series C in 2022
Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Jasper Health

Series A in 2022
Founded in 2018, Jasper Health is a digital platform that provides personalized psychosocial support to patients living with cancer. It offers telemedicine services and the Cancer Care Companion, a smart planner that helps manage appointments, track symptoms, and coordinate care.

Maze Therapeutics

Venture Round in 2022
Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Ophelia

Series B in 2021
Ophelia Health, Inc., established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, providing necessary medications at home. Ophelia differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.

Cadence Solutions

Series B in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.

Variant Bio

Series B in 2021
Variant Bio Inc. is a biotechnology company focused on developing therapeutics through the exploration of human genetic diversity. Founded in 2018 and headquartered in Seattle, Washington, the company seeks to identify individuals and populations exhibiting extreme outlier traits relevant to various medical conditions. By employing advanced sequencing technologies, statistical genetics, and machine learning, Variant Bio analyzes the genetic underpinnings of these traits to uncover new therapeutic targets. The company's mission is to enhance global health by addressing unmet medical needs, particularly in areas such as neurodegenerative, autoimmune, and cardiometabolic diseases.

Beacon Biosignals

Series A in 2021
Beacon Biosignals is a company focused on enhancing human health through the application of artificial intelligence in the analysis of brain activity. It has developed a platform that provides rapid and accurate electroencephalogram (EEG) reports, streamlining the diagnostic process by eliminating the need for adjudication and utilizing improved criteria for inclusion and exclusion. The platform captures real-time brain activity, supporting healthcare professionals in the study of neurological and psychiatric disorders. By enabling more precise quantification of treatment plans and helping identify optimal patient populations, Beacon Biosignals aims to facilitate targeted interventions and advance the field of brain analytics.

Zerigo Health

Series B in 2021
Zerigo Health develops innovative medical devices that deliver narrowband UVB light therapy for chronic skin conditions such as psoriasis, eczema, and vitiligo. Their flagship product, Clarify Medical, is a connected phototherapy system that enables patients to administer treatments at home under physician prescription, ensuring clinical precision while promoting convenience and empowerment.

Better Health

Series A in 2021
Better Health is a digital platform facilitating peer-to-peer support and supplies management for individuals with chronic conditions such as ostomy, wounds, diabetes, retention, and incontinence. Trusted by major healthcare payers and providers, it improves patient outcomes and reduces care costs through education, engagement, and adherence.

Sprinter Health

Series A in 2021
Sprinter Health is a mobile healthcare provider that sends full-time nurses and phlebotomists to patients' homes for preventive care services.

Loop

Series A in 2021
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

Cadence Solutions

Series A in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.

Aidoc

Series C in 2021
Aidoc develops an AI-driven platform that analyzes medical images directly after scanning, suggesting prioritization of time-sensitive pathologies and activating multidisciplinary teams to improve patient outcomes.

Osmind

Series A in 2021
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.

PathAI

Series C in 2021
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Ophelia

Series A in 2021
Ophelia Health, Inc., established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, providing necessary medications at home. Ophelia differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.

Oath Care

Seed Round in 2021
Oath Care is developing an innovative model of group-based, continuous healthcare aimed at improving health outcomes for children. The company has created an online platform that connects medical providers with families, fostering intimate connections and shared experiences among parents. This platform offers a range of support options, including group chat and one-on-one video calls, allowing patients to access both medical and emotional assistance tailored to their individual needs. By prioritizing collaboration and communication, Oath Care seeks to enhance the overall healthcare experience for the next generation.

Ro

Series D in 2021
Ro is a telehealth company founded in New York City in 2017. It operates digital health clinics for men's and women's health, smoking cessation, and offers a vertically integrated primary care platform that provides high-quality, affordable healthcare without the need for insurance.

Ossium Health

Series B in 2021
Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

Sprinter Health

Seed Round in 2021
Sprinter Health is a mobile healthcare provider that sends full-time nurses and phlebotomists to patients' homes for preventive care services.

Circulo

Series A in 2021
Circulo Health is a Medicaid insurance company based in Columbus, Ohio, focused on delivering technology-enabled care to vulnerable populations, particularly the sickest and poorest individuals. The company operates a medical insurance platform designed to improve access to healthcare services for underprivileged communities. By partnering with hospitals, Circulo Health aims to ensure that patients can receive necessary medical care in a more affordable manner, thereby addressing the healthcare needs of those who are often overlooked. Through its innovative approach, Circulo is positioned as a leader in the evolving insurtech landscape, working to improve health outcomes for marginalized groups across the nation.

Plume Clinic

Series A in 2021
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.

Elephant Healthcare

Series A in 2021
Founded by doctors in 2018, Elephant Healthcare is a London-based technology company dedicated to addressing global healthcare challenges. It designs and develops a digital health system that aims to connect all aspects of the healthcare ecosystem, transforming primary care, saving lives, and reducing costs.

Curai Health

Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Story Health

Seed Round in 2020
Story Health Corporation is a healthcare technology company founded in 2020 and based in Saratoga, California. The company develops intelligent embedded virtualized clinical care software tools designed to assist healthcare specialists, including neurologists and primary care physicians, in understanding medical situations and making informed clinical decisions. Story Health's platform utilizes data from high-frequency sources to enhance therapy management through virtual protocols and adaptive machine learning. By focusing on patient-centered design, Story Health aims to bridge the gap between clinical evidence and real-world patient experiences, enabling clinicians to effectively address the physiological effects of disease and therapy.

Osmind

Seed Round in 2020
Osmind Inc. is a San Francisco-based public benefit corporation founded in 2020 that specializes in developing healthcare software tailored for mental health providers and their patients. The company focuses on advancing evidence-based medicine to support individuals suffering from moderate to severe mental health conditions. Osmind's electronic health record platform is designed specifically for clinicians and researchers, facilitating interventional treatment workflows. It includes features such as journaling tools and support for health plan reimbursement, empowering healthcare professionals to implement innovative therapeutic approaches and precision psychiatry. By providing robust technology, Osmind aims to inform best practices in patient care and contribute to the development of new life-saving mental health treatments.

Ro

Series C in 2020
Ro is a telehealth company founded in New York City in 2017. It operates digital health clinics for men's and women's health, smoking cessation, and offers a vertically integrated primary care platform that provides high-quality, affordable healthcare without the need for insurance.

Ophelia

Seed Round in 2020
Ophelia Health, Inc., established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, providing necessary medications at home. Ophelia differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.

Karius

Series B in 2020
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.

PathAI

Series B in 2019
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Curai Health

Series A in 2018
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Ro

Seed Round in 2017
Ro is a telehealth company founded in New York City in 2017. It operates digital health clinics for men's and women's health, smoking cessation, and offers a vertically integrated primary care platform that provides high-quality, affordable healthcare without the need for insurance.

PathAI

Series A in 2017
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.

Commure

Seed Round in 2017
Commure is a healthcare technology company that provides an open, cloud-based operating system and developer platform for building interoperable healthcare software. The platform unifies disparate datasets, enables building and deploying health applications on a secure foundation based on HL7 FHIR, and offers an API server, security framework, event service bus, EHR integration, API gateway, flexible data store, UI components, and terminology services. It supports clinicians, nurses, patients, and other health professionals to access and share insights, accelerate software innovation, and collaborate across care facilities, health systems, and payers. The company partners with health systems and digital innovators to advance care delivery with a suite of applications and tools. Commure is headquartered in San Francisco, with offices in Boston, Montreal, and Bogota.

PatientBank

Seed Round in 2016
PatientBank is a medical information-sharing platform that facilitates the online request and management of medical records from various healthcare providers, including doctors and hospitals. The service enables patients to gather and store their medical records securely, allowing for easy sharing with care providers, hospitals, and family members. By streamlining the process of retrieving and sharing medical information, PatientBank enhances the efficiency of health checkups and improves communication between patients and their healthcare teams. The platform aims to empower individuals in managing their health information, making it more accessible when needed.

TearScience

Series D in 2016
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Corvia

Series D in 2014
Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Corvia

Series C in 2013
Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

Oceans Healthcare

Venture Round in 2013
Oceans Healthcare is a behavioral health provider established in 2004, dedicated to healing and long-term recovery for individuals, particularly older adults. The company operates 33 locations, including 23 inpatient hospital campuses across the Southeast, and specializes in addressing cognitive and mental health symptoms such as depression, anxiety, and schizophrenia, as well as behavioral changes related to medication management and substance abuse. In 2020, Oceans treated over 18,000 individuals, demonstrating a commitment to comprehensive care throughout the recovery process. The company is recognized for its consistent achievement of high performance metrics on national quality and safety measurements, as assessed by the Centers for Medicare and Medicaid Services and The Joint Commission. Additionally, Oceans Healthcare has earned a place on the Inc. 5000 list of the fastest-growing private companies in America for four consecutive years.

SynapDx

Series B in 2012
SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

Aidin

Venture Round in 2012
Aidin streamlines post-acute care coordination by automating provider listings and offering patient reviews. It empowers patients in decision-making while tracking outcomes for improved hospital case management.

Humedica

Venture Round in 2012
Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

OvaScience

Series B in 2012
OvaScience, Inc. is a fertility company focused on discovering and commercializing innovative treatment options for women experiencing infertility. Founded in 2011 and headquartered in Waltham, Massachusetts, OvaScience developed proprietary technology based on the identification of egg precursor (EggPC) cells, enabling new approaches to fertility treatments. Its key offerings include OvaPrime, which aims to restore a woman's natural egg production by utilizing her own EggPC cells; OvaTure, which matures these cells into fertilizable eggs outside the body without hormone stimulation; and AUGMENT, which enhances fertilization and pregnancy rates using mitochondria from the woman’s EggPC cells. The company’s technology is exclusively licensed from Harvard Medical School and Massachusetts General Hospital, and it has been supported by a team of experts in reproductive science and embryology. OvaScience was initially known as Ovastem, Inc. before rebranding in 2011. In December 2018, OvaScience was acquired by Millendo Therapeutics, marking a significant shift in its operational focus.

Humedica

Venture Round in 2011
Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

SynapDx

Series A in 2010
SynapDx is a diagnostic company based in Lexington, Massachusetts, focused on providing laboratory testing services aimed at the early detection of autism spectrum disorders (ASDs) in children. Established by Stanley Lapidus, the company develops blood-based diagnostic tests that leverage insights from experts in ASD and gene expression. These tests are designed to assist healthcare providers in identifying early symptoms of autism, addressing the need for timely intervention in a condition that affects approximately 1 in 110 children in the United States. Through its innovative approach, SynapDx aims to enhance the diagnostic process for developmental disorders and improve outcomes for affected children and their families.

TearScience

Series C in 2010
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, specializing in the identification, diagnosis, and treatment of meibomian gland disease (MGD), a primary cause of dry eye affecting millions worldwide. Founded in 2005, TearScience has developed innovative devices to address evaporative dry eye, including the LipiFlow Activator, which delivers automated therapeutic energies to treat the meibomian glands, and the LipiScan, an imaging tool that allows eye care professionals to assess gland health. The company's integrated system enables effective management of MGD, which is often underestimated despite being a leading contributor to dry eye symptoms such as irritation, dryness, and visual disturbances. As a subsidiary of Johnson & Johnson Surgical Vision, TearScience continues to advance its mission of improving patient outcomes through early detection and treatment of this chronic condition.

Humedica

Series A in 2009
Humedica is a clinical intelligence company that specializes in health analytics, offering tools designed for hospitals, physicians, and life sciences organizations. The company transforms unconnected data from various sources into actionable insights, enabling healthcare providers to make informed decisions. One of its key products, Humedica MinedShare, serves as a platform for clinical, operational, and financial benchmarking across the continuum of care, facilitating improved performance and outcomes in the healthcare sector. Through its innovative solutions, Humedica aims to enhance the quality of care and operational efficiency within the healthcare industry.

Imprivata

Series C in 2008
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

MovingHealth

Seed Round in 2007
Movinghealth, Inc. provides Web based health care services to patients and consumers. The company offers wellbeing news and articles, medical reference content databases, and online therapeutic remedial imagery and graphics. Movinghealth was founded in 2007 and is based in Cambridge, Massachusetts.

Imprivata

Series B in 2006
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Imprivata

Series A in 2005
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Imprivata

Series A in 2002
Imprivata, Inc. is a provider of information technology security and identity solutions specifically designed for the healthcare industry. Headquartered in Lexington, Massachusetts, the company offers a comprehensive platform that addresses security and compliance challenges faced by healthcare organizations. Key products include Imprivata OneSign, which integrates single sign-on and authentication management to streamline access to workstations and applications; Imprivata Cortext, a secure messaging platform that enables compliant communication among healthcare providers; and Imprivata Confirm ID, which simplifies identity proofing and enforces two-factor authentication for electronic health records. Additionally, Imprivata PatientSecure enhances patient safety by reducing duplicate medical records and identity-related fraud. The company's solutions are utilized in over 45 countries, supporting healthcare organizations in managing and securing digital identities effectively. Founded in 2001, Imprivata remains committed to improving the efficiency and security of healthcare workflows.

Sprinter Health

Sprinter Health is a mobile healthcare provider that sends full-time nurses and phlebotomists to patients' homes for preventive care services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.